Most Innovative Cancer Drugs Are Not Prioritised

Most Innovative Cancer Drugs Are Not Prioritised

In an overview of all drugs licenced through the European Medicines Agency (EMA) from 2000 to the end of 2016, the research team from The Institute of Cancer Research (London) found that increasing numbers of drugs are being authorised. The average number of drugs subject to the EMA licencing increased from a median of six per year for 2000–2008, to 13.5 per year for 2009–2016. Between 2000 and 2016, there were 64 drug authorisations for haematological, 15 for breast, and 12 for skin cancer, but none for oesophageal, brain, bladder or uterine cancer.




Next Article

  • How Robotic Process Automation (RPA) Can Improve Clinical Outcomes

    How Robotic Process Automation (RPA) Can Improve Clinical Outcomes

    In an effort to streamline business processes, more CIOs are turning to robotic process automation, or RPA. KPMG estimates the value of the global IT robotic automation market to reach roughly $5 …

    Posted Feb 3, 2020robotic process automation

Did you find this useful?

Medigy Innovation Network

Connecting innovation decision makers to authoritative information, institutions, people and insights.

Medigy Logo

The latest News, Insights & Events

Medigy accurately delivers healthcare and technology information, news and insight from around the world.

The best products, services & solutions

Medigy surfaces the world's best crowdsourced health tech offerings with social interactions and peer reviews.


© 2024 Netspective Media LLC. All Rights Reserved.

Built on Mar 28, 2024 at 3:00am